Dissociated amyloid-β antibody levels as a serum biomarker for the progression of Alzheimer’s disease: A population-based study

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[2]  P. Scheltens,et al.  Quantification of amyloid-beta 40 in cerebrospinal fluid. , 2009, Journal of immunological methods.

[3]  S. Greenberg,et al.  Cerebrospinal fluid amyloid β40 is decreased in cerebral amyloid angiopathy , 2009, Annals of neurology.

[4]  C. Adler,et al.  Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease , 2009, Alzheimer's & Dementia.

[5]  G. Perry,et al.  Antigen–antibody dissociation in Alzheimer disease: a novel approach to diagnosis , 2008, Journal of neurochemistry.

[6]  J. Troncoso,et al.  Maximizing the Potential of Plasma Amyloid-Beta as a Diagnostic Biomarker for Alzheimer’s Disease , 2008, NeuroMolecular Medicine.

[7]  Georg Kemmler,et al.  Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine , 2008, Neurobiology of Aging.

[8]  A. Goate,et al.  Clearance of amyloid-β by circulating lipoprotein receptors , 2007, Nature Medicine.

[9]  Xiongwei Zhu,et al.  Vascular oxidative stress in Alzheimer disease , 2007, Journal of the Neurological Sciences.

[10]  N. Fullwood,et al.  Plasma amyloid-β concentrations in Alzheimer's disease: an alternative hypothesis , 2006, The Lancet Neurology.

[11]  Hyoung-Gon Lee,et al.  Neuropathology of Alzheimer disease: pathognomonic but not pathogenic , 2006, Acta Neuropathologica.

[12]  J. Morris,et al.  Neuropathologic Criteria for Diagnosing Alzheimer Disease in Persons with Pure Dementia of Alzheimer Type , 2004, Journal of neuropathology and experimental neurology.

[13]  S. Murayama,et al.  Neuropathological diagnostic criteria for Alzheimer's disease , 2004, Neuropathology : official journal of the Japanese Society of Neuropathology.

[14]  E. Zamrini,et al.  Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Aβ and RAGE peptides , 2004, Neurobiology of Aging.

[15]  M. Luca,et al.  Platelets provide human tissue to unravel pathogenic mechanisms of Alzheimer disease , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[16]  J. Schiller,et al.  Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice , 2004, BMC Neuroscience.

[17]  Kaj Blennow,et al.  Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRX.

[18]  R. Mayeux,et al.  Plasma A&bgr;40 and A&bgr;42 and Alzheimer’s disease: Relation to age, mortality, and risk , 2003 .

[19]  N. Relkin,et al.  Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals , 2002, Experimental Gerontology.

[20]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[21]  W. Oertel,et al.  Reduced levels of amyloid β-peptide antibody in Alzheimer disease , 2001, Neurology.

[22]  K. Blennow,et al.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.

[23]  K. Blennow,et al.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.

[24]  L. Ferrucci,et al.  Formal education as an effect modifier of the relationship between Mini-Mental State Examination score and IADLs disability in the older population , 1997, Aging.

[25]  B. Hyman,et al.  Amyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma* , 1996, The Journal of Biological Chemistry.

[26]  Hans Förstl,et al.  Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay* , 1996, The Journal of Biological Chemistry.

[27]  W. M. van der Flier,et al.  CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. , 2009, Journal of Alzheimer's disease : JAD.

[28]  Xiongwei Zhu,et al.  Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies. , 2008, Journal of Alzheimer's disease : JAD.

[29]  A. Goate,et al.  Clearance of amyloid-beta by circulating lipoprotein receptors. , 2007, Nature medicine.

[30]  N. Fullwood,et al.  Plasma amyloid-beta concentrations in Alzheimer's disease: an alternative hypothesis. , 2006, The Lancet. Neurology.

[31]  L S Honig,et al.  Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. , 2003, Neurology.